SCHEMBL23706010

SCHEMBL23706010

CC1(C=O)CCc2ccc(C(=O)O)cc21

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM1A O60341 1/20 0.52
KDM4E B2RXH2 3/20 0.47
ALDH1A1 P00352 3/20 0.47
MAPT P10636 2/20 0.47
POLB P06746 2/20 0.47
BLM P54132 2/20 0.47
CYP2C19 P33261 2/20 0.47
GRM1 Q13255 1/20 0.47
TDP1 Q9NUW8 1/20 0.47
MEN1 O00255 1/20 0.47
MAPK1 P28482 1/20 0.47
KMT2A Q03164 1/20 0.47
RARB P10826 11/20 0.44
RXRA P19793 10/20 0.44
RARG P13631 10/20 0.44
RARA P10276 9/20 0.44
RXRB P28702 5/20 0.44
RXRG P48443 3/20 0.44
CYP26A1 O43174 2/20 0.44
CYP26B1 Q9NR63 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30097044 1.00 KDM1A (0.52) KDM1AKDM4EALDH1A1MAPTPOLB
SCHEMBL30042034 0.75 KDM1A (0.52) KDM1AKDM4EALDH1A1MAPTPOLB
SCHEMBL23705938 0.75 KDM1A (0.52) KDM1AKDM4EALDH1A1MAPTPOLB
SCHEMBL19764448 0.75 KDM1A (0.73) KDM1AKDM4EALDH1A1MAPTPOLB
SCHEMBL23706158 0.75 KDM1A (0.52) KDM1AKDM4EALDH1A1MAPTPOLB
SCHEMBL30042598 0.75 KDM1A (0.52) KDM1AKDM4EALDH1A1MAPTPOLB
SCHEMBL9551744 0.74 RXRA (0.63) KDM1AKDM4EALDH1A1MAPTPOLB
SCHEMBL23705405 0.74 KDM1A (0.51) KDM1AKDM4EALDH1A1MAPTPOLB
SCHEMBL24401007 0.73 KDM1A (0.58) KDM1AKDM4EALDH1A1MAPTPOLB
SCHEMBL8458491 0.73 ALDH1A1 (0.65) KDM1AKDM4EALDH1A1MAPTPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12441726-B2 Compounds and uses thereof FOGHORN THERAPEUTICS, INC. (US) 2025-10-14 US disclosed
CN-115297861-B Compounds and uses thereof 福宏治疗公司 2024-07-12 CN disclosed
US-20230145003-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. 2023-05-11 US disclosed
US-20230145003-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. 2023-05-11 US disclosed
US-20230145003-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. 2023-05-11 US disclosed
EP-4096667-A1 COMPOUNDS AND USES THEREOF Foghorn Therapeutics Inc. (US) 2022-12-07 EP disclosed
CN-115297861-A Compound and use thereof 福宏治疗公司 2022-11-04 CN disclosed
WO-2021155320-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. (US) 2021-08-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12441726-B2 Compounds and uses thereof VHL, CLN6, TFEB KDM1A 2149/4885KDM4E 1848/4885ALDH1A1 2571/4885
US-20230145003-A1 COMPOUNDS AND USES THEREOF VHL, CLN6, TFEB KDM1A 2149/4885KDM4E 1848/4885ALDH1A1 2571/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.